Status:
COMPLETED
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units
Lead Sponsor:
Corewell Health East
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophyla...
Eligibility Criteria
Inclusion
- Age \>18 years old
- positive reverse transcription-polymerase chain reaction (rRT-PCR) test for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens.
- Intensive care unit (ICU) patient or Step-down unit (SDU) patient on invasive mechanical ventilation, BiPAP, 100% non-rebreather mask, or high flow oxygen or supplemental oxygen of at least 4 liters per minute nasal cannula.
- peak d-dimer levels exceeding 1,000 mcg/mL at any time during admission.
Exclusion
- Hospital length of stay less than 5 days.
- Hemorrhage before ICU/SDU admission.
- Treatment with an anticoagulant other than low molecular weight heparin or unfractionated heparin.
- Constant treatment with the same dose of anticoagulant for less than 5 days.
Key Trial Info
Start Date :
March 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2020
Estimated Enrollment :
704 Patients enrolled
Trial Details
Trial ID
NCT04829552
Start Date
March 10 2020
End Date
April 15 2020
Last Update
April 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beaumont Health System (BHS)
Royal Oak, Michigan, United States, 48073